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Abstract
Background: In this study we investigated the antiatherogenic effect of dietary enrichment of a combination of
extra virgin olive oil (EVO) and seal oil on apolipoprotein E-deficient (apoE
-/-).
Methods: Six-week-old female and male apoE
-/- mice were for 12 weeks fed a lipid rich diet containing 19.5% fat
and 1.25% cholesterol without any supplement, with 1% (wt/wt) mixture of extra virgin olive and seal oil (EVO/n-3),
or 1% corn oil, respectively.
Results: Supplementation with the combination of EVO/n-3 significantly reduced atherosclerotic lesion formation
in the aortic arch, thoracoabdominal, and total aorta of female apoE
-/-mice. The effect was less pronounced in
male mice and significant reduction was only observed in the thoracoabdominal region of the aorta. There were
no differences or changes in dietary intake or body weight gain. However, compared to the other groups, plasma
levels of triglycerides were reduced in both female and male mice fed the EVO/n-3 mixture. Male mice on both
treatments showed reduced plasma cholesterol compared to the control mice after 12 weeks on diet.
Conclusion: Dietary supplementation of a marine/olive oil combination inhibits atherosclerotic lesion formation in
the female apoE
-/- mice by antithrombotic, antihypertriglyceridemic, and antioxidant effects.
Introduction
Atherosclerosis is a disease with a multi-faceted aetiol-
ogy, and diet is one of the most important environmen-
tal factors influencing the development of cardiovascular
disease (CVD). The Mediterranean diet rich in extra vir-
gin olive oil (EVO) has been associated with reduced
rates of cardiovascular disease (CVD) [1-4]. EVO has a
healthy fatty acid content with a high content of mono-
unsaturated fatty acids (MUFA), mainly oleic acid
(C-18:1n-9). Most other oils with a similar fatty acid
composition are exposed to a refining process before
consumption, in which presumably healthy components
are removed or reduced. Unlike these, first-press EVO
retains the important minor mainly phenolic com-
pounds having properties considered to be anti-oxidant
and anti-atherosclerotic [5]. Human consumption of
EVO reduces major risk factors of atherosclerosis by
improving the lipoprotein profile, blood pressure,
glucose metabolism, and oxidative stress [6]. Similarly,
considerable attention has been paid to the potential
health benefits of the Greenland Inuit diet rich in fish,
meat and blubber from marine mammals (seal and
whale) resulting in a high dietary intake of long chain
n-3 polyunsaturated fatty acids (PUFA), as this dietary
regime also has been associated with a very low inci-
dence of CVD [7]. PUFA has been considered as the
major cardioprotective component in fish.
Research in our laboratories has previously demon-
strated that co-supplementation of extra virgin olive oil
and marine n-3 PUFA exerts anti-inflammatory effects
by inhibiting lipopolysaccharide-induced monocyte acti-
vation in vitro [8,9], hence we hypothesized that a com-
bination of EVO and seal oil should bring about a
synergistic beneficial effect and reduce the development
of CVD through prevention of oxidation of PUFAs and
vascular inflammation. Intake of both marine PUFA and
EVO has been associated with protection against coron-
ary heart disease and sudden death. However, direct
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end, Apolipoprotein (apo) E-deficient mice (6 weeks)
were fed an atherogenic Western type diet (high fat,
high cholesterol) enriched with i) 1% of a combination
of EVO and seal oil (EVO/n-3), ii)1 %c o r no i l( C O R N )
or iii)n os u p p l e m e n t( W D )f o r1 2w e e k st os t u d yt h e
impact on plasma lipids and the development of athero-
sclerosis. ApoE-deficient mice spontaneously develop
atherosclerosis with features similar to those observed in
humans and is widely used to study the effect of diets
on lipid metabolism and atherosclerosis [10,11].
Methods
Animals and diets
In total, 62 (30 females and 32 males, weighting 16.9 ±
1.2 g and 20.2 ± 1.2 g, respectively) ApoE
-/- mice
(B6.129P2-Apoe
tm1UncN11) 5 weeks of age obtained from
Taconic (Taconic M&B, Ry, Denmark) were ear-marked
and randomly allotted to three experimental groups,
with equal numbers of cages in same-sex groups. This
study was approved by the Institutional Animal
Research Committee, and all experiments were per-
formed following FELASA recommendation and accord-
ing to the Belgian legislation on care and use of
experimental animals. All animals were maintained in
the same room at a room temperature of 21 ± 1°C and
50 ± 10% relative humidity, on a 12 h day/12 h night
cycle (light on at 06:00 h) in a conventional laboratory
animal unit. All animals were kept in type III Makrolon
cages (Scanbur, Køge, Denmark) (37×21×15 cm). After
one week of acclimation, the mice were fed a powdered
atherogenic diet (1.25% cholesterol, 0% cholic acid, and
19.5% crude fat; ssniff Spezialdiäten GmbH, Soest, Ger-
many) ad libitum for 12 weeks. The mice were divided
into 3 groups of each sex and given the standard diet
without any modification, or supplemented with 1% (w/
w) mixture of EVO and seal oil (EVO/n-3; Olivita™,
Olivita AS, Tromsø, Norway) or 1% (w/w) corn oil
(CORN), respectively. The experimental diets were
stored at 4°C, changed twice each week, and food con-
sumption was recorded for every cage.
Analysis of Atherosclerosis - Whole mount en face
evaluation
After 12 weeks on the high-fat diet, mice were fasted for
4 h and anesthetized by intra-peritoneal pentobarbital
(60 mg/kg pentobarbital; Nembutal, Abbott Labora-
tories), blood was drawn by retroorbital puncture, and
the whole animal was perfused through the left ventricle
with sterile saline (0.9%) for 5 min, followed by 1% par-
aformaldehyde (PFA) in P B S ,p H7 . 4f o r5m i n .T h e
entire aorta from the proximal ascending aorta to the
bifurcation of the iliac arteries was dissected and cleaned
in situ from the periadventitial tissue and opened
longitudinally. After fixation in 1% PFA overnight, aortas
were washed in PBS, soaked briefly in 78% methanol,
stained with oil red O (ORO) for 30 min while shaking,
and destained in 78% methanol for 2×5 min and
mounted en face on slides under coverslips within
Kaiser’s glycerol gelatin (Merck, Darmstadt, Germany).
ORO was prepared as a 0.2% stock in methanol and
3 5m ls t o c kw a sm i x e dw i t h1 0m lo f1MN a O Ha n d
filtered just before staining. Slides were allowed to dry
for 2 days and the luminal side of the vessels were
photographed using a Zeiss AxioPlan 2 imaging micro-
scope equipped with a Zeiss AxioCam HrC camera.
Photographs were evaluated for lesion area by morpho-
metry and the extent of lesion development was
reported as percentage of the total area of a given artery
that was occupied by atherosclerotic lesions.
Plasma Cholesterol and Triacylglycerol Levels
Mice were fasted for 4 hours, anesthetized with intra-
peritoneal pentobarbital (60 mg/kg Nembutal) before
collection of venous blood from the retro-orbital sinus
into a heparinised capillary tube. Fasting plasma samples
were obtained for total cholesterol and triacylglycerol
determinations at baseline, after 6 weeks on the experi-
mental diet, and at the end of the study (12 weeks).
Plasma was isolated by centrifugation at 3000 g for
1 0m i n u t e sa t4 ° Ca n ds t o r e da t- 2 0 ° C .E n z y m a t i cm e a -
surements of total cholesterol and triacylglycerol levels
were performed using standard methods at the clinical
chemistry department, UZ Leuven, Belgium.
Fatty acid composition of the diets
Dietary fatty acids (FA) was extracted and analyzed as
described previously [12].
Oxidation stability of the oils tested
An oxygen consumption method (Oxidograph, Mikrolab
Aarhus, Brabrand, Denmark) was used to measure the
in vitro oxidation stability of commercial a n-3 concen-
trate, seal oil, EVO, and a combination of seal oil and
EVO (test conditions: temperature 70°C, sample 5 g of
oil, rate 1 s-1) [13]. The induction period (hours) until
the PUFA started to oxidize was measured to compare
the oxidation stability of the tested oils. The Oxidograph
measurements were duplicated and mean values with
standard deviations were reported for each case.
Statistical Analyses
All of the analyses were performed using SPSS for Win-
dows (release 15.0.1; SPSS, Inc., Chicago, IL, USA).
Unless otherwise stated, results are presented as mean ±
standard deviation (SD). The Kolmogorov-Smirnov and
Shapiro-Wilk tests were used to determine the distribu-
tion of the variables, and non-normally distributed vari-
ables were log transformed before statistical analysis.
Eilertsen et al. Lipids in Health and Disease 2011, 10:41
http://www.lipidworld.com/content/10/1/41
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at baseline or the impact of treatment on the changes in
each group was determined using one-way analysis of
variance (ANOVA) with post hoc comparisons of
the variables using the Tukey’s test. Within-group com-
parisons during the time-course of the experiment were
performed using paired-group student’st - t e s to rM a n n -
Whitney U-test where appropriate. Differences at the
level of P < 0.05 were considered statistically significant.
Results
The antioxidant effect of EVO on oxidation of seal oil at
70°C
The oxidation stability of the PUFAs was determined
using the Oxidograph apparatus. A longer induction
period is an index for the resistance to oxidation. When
the seal oil alone was subjected to oxidation at 70°C, the
induction period was 2.1 hrs compared to 38.3 hrs for
the combination of seal oil and EVO used in this study
(values are average of 2 measurements). In comparison
oxygen consumption started at 0.2 hrs for the commer-
cial omega-3 concentrate.
Fatty acid composition of the diets
As shown in table 1, the PUFA enriched diets contained
less saturated fatty acids (corn: 55.0 ± 0.2 g/100 g lipids,
EVO/n-3: 55.0 ± 0.1 g/100 g lipids) compared to the con-
trol diet (56.5 ± 0.4 g/100 g lipids). The corn oil-enriched
diet contained more C18:2n-6 linoleic acid (9.5 ± 0.1
g/100 g lipids) compared to the other experimental
diets (control: 7.0 ± 0.1 g/100 g lipids, EVO/n-3: 6.9 ±
0.0 g/100 g lipids), whereas the content of linolenic acid
(C18:3n-3) was identical between all diets (0.6 ± 0.0 g/100
g lipids). Compared to the other two diets the EVO/n-3
diet contained more MUFA, especially C18:1n-9 oleic acid
(31.3 ± 0.0 g/100 g lipids vs control: 29.9 ± 0.2 g/100 g
lipids, corn: 30.1 ± 0.1 g/100 g lipids), and finally the EVO/
n-3 diet was the only diet containing detectable amounts
of the marine n-3 fatty acids eicosapentaenoic acid; (EPA;
C20:5n-3), docosapentaenoic acid (DPA; C22:5n-5), and
docosahexaenoic acid (DHA; C22:6n-3).
Mice growth and food intake
All the mice thrived and gained weight throughout the
study. There were no apparent differences in growth
between the different groups, or compared to mice kept
on standard chow. Figure 1 shows the changes in body
weight of the groups from the beginning to the end of
the study.
Plasma total cholesterol and triacylglycerol levels
Initial plasma total cholesterol and triglyceride concen-
trations were between 2.38 and 7.55 mmol/l in all
groups at the start of the study (Table 2). The female
mice fed EVO/n-3 had higher plasma total cholesterol
levels at the start of the study compared to the CORN
group (5.79 ± 1.20 vs 3.97 ± 0.63, p < 0.01), and after
6 weeks on diet plasma TC was higher compared to the
control group (19.4 ± 3.70 vs 14.1 ± 3.67, p < 0.01).
Both cholesterol and triacylglycerol levels tended to
decrease towards the end of the intervention where
plasma cholesterol was similar among the females. For
all the groups fed the western-type diets (control, corn
oil and EVO/n-3) a two-to-five-fold increased plasma
TC (P < 0.05) compared to baseline cholesterol was
observed, whereas plasma triacylglycerol levels generally
decreased during the study period. In male mice, plasma
TC increased significantly for all groups between the
start and week 6. After 12 weeks on diet, plasma choles-
terol was significantly lower for males fed either oil
treatment compared to the controls. At the end of the
12-wk experiment, plasma TC for the chow-fed male
mice was 6.95 ± 0.90 mmol/l.
Atherosclerotic Lesions
The influence of the combination of EVO and seal oil on
the development of atherosclerosis was analyzed in both
female and male apoE
-/- mice. En face atherosclerotic
lesions in the opened aortas were evaluated as percent area
positive to lipid ORO-staining both in the whole aorta and
regionally, calculating the percent area staining red in the
aortic arch, in the thoracoabdominal part of the descending
aorta and in the infrarenal part down to the iliac bifurca-
tion. The lesions were mainly distributed in the aortic arch
and the areas surrounding the branching points of the
Table 1 Fatty acid composition of the experimental diets
(g/100g lipids; n = 3)
Fatty acids Control Corn oil EVO
1/n-3
C14:0 0.25 ± 0.01 0.28 ± 0.02 0.38 ± 0.02
C16:0 23.61 ± 0.20 23.32 ± 0.22 23.16 ± 0.03
C16:1n-7 0.23 ± 0.00 0.23 ± 0.00 0.73 ± 0.01
C18:0 31.45 ± 0.19 30.25 ± 0.09 30.26 ± 0.08
C18:1n-9 29.90 ± 0.24 30.12 ± 0.07 31.30 ± 0.03
C18:1n-7 0.54 ± 0.01 0.55 ± 0.01 0.66 ± 0.01
C18:2n-6 7.03 ± 0.08 9.49 ± 0.05 6.94 ± 0.01
C18:3n-3 0.63 ± 0.00 0.64 ± 0.00 0.64 ± 0.00
C20:0 1.00 ± 0.01 0.98 ± 0.01 0.97 ± 0.01
C20:1n-9 0.12 ± 0.00 0.10 ± 0.00 0.37 ± 0.03
C22:0 0.21 ± 0.00 0.20 ± 0.00 0.20 ± 0.00
C20:5n-3 nd nd 0.18 ± 0.00
C22:5n-3 nd nd 0.11 ± 0.00
C22:6n-3 nd nd 0.23 ± 0.01
Σ saturated FA
2 56.52 ± 0.36 55.03 ± 0.20 54.98 ± 0.09
Σ monounsaturated FA 30.70 ± 0.29 30.93 ± 0.08 33.06 ± 0.04
Σ polyunsaturated FA 7.66 ± 0.08 10.13 ± 0.05 8.10 ± 0.02
n-3 polyunsaturated FA 0.63 ± 0.00 0.64 ± 0.00 1.16 ± 0.02
1EVO, extra virgin olive oil. FA, fatty acids.
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aortas from the EVO/n-3-fed mice compared to both the
other dietary groups. This effect was particularly pro-
nounced for the female mice (Figure 2), where the plaque
burden in the aortic arch of the EVO/n-3-group (5.2 ±
2.3%) were reduced by 61% (P < 0.001) and 63% (P <
0.001) compared to the control group (13.5 ± 2.9%) and
the CORN-enriched group (13.9 ± 3.1%), whereas there
were no significant differences between the control group
and the CORN-enriched group. Also in the thoracoabdom-
inal region of the aorta, (EVO/n-3 1.60 ± 0.53%, control
group 2.62 ± 0.57%; P < 0.01, and corn oil 2.67 ± 0.52%; P
< 0.01), and in the entire aorta subjected to analysis, (EVO/
n-3 2.54 ± 0.45%, control group 5.85 ± 0.35%; P < 0.01,
and CORN 5.55 ± 0.67%; P < 0.01), enrichment with the
EVO/n-3 combination significantly reduced atherogenesis.
Table 2 Plasma lipids in the six different study groups
Cholesterol (mmol/l) Triglycerides (mmol/l)
Week 0 Week 6 Week 12* Week 0 Week 6 Week 12
Females
No supplement (n = 11) 4.93 ± 1.28 14.1 ± 3.67*
,a 12.4 ± 1.63* 0.36 ± 0.10 0.28 ± 0.09 0.41 ± 0.45
a
EVO
1/n-3 (n = 11) 5.79 ± 1.20
a 19.4 ± 3.70*
,b 13.9 ± 3.76* 0.49 ± 0.27 0.32 ± 0.10 0.22 ± 0.03*
,b
Corn oil (n = 08) 3.97 ± 0.63
b 15.9 ± 1.33* 14.1 ± 1.80* ND ND ND
Males
No supplement (n = 11) 3.99 ± 1.26 16.1 ± 5.90* 20.2 ± 5.11*
,a 0.42 ± 0.20 0.32 ± 0.16 0.46 ± 0.24
EVO/n-3 (n = 11) 4.57 ± 1.18 13.5 ± 2.62* 12.7 ± 4.08*
,b 0.42 ± 0.14 0.25 ± 0.05* 0.23 ± 0.02*
,b
Corn oil (n = 10) 3.91 ± 0.60 15.0 ± 3.53* 14.7 ± 3.75*
,b 0.27 ± 0.13 0.34 ± 0.12 0.51 ± 0.31
a
Chow (n = 05) 5.21 ± 1.55 ND 6.95 ± 0.90 0.53 ± 0.40 ND 0.38 ± 0.16
Cholesterol and triglyceride levels at the start of the study (week 0), after 6 weeks and at the end of the study (week 12). Values are mean ± S.D. Means within
the same column bearing different superscripts are significantly different (p < 0.05 for individual comparison using the Tukeys’ post hoc test after ANOVA).
*Value significantly different from start concentration (week 0, P < 0.05)
1EVO, extra virgin olive oil. Significant differences between groups at certain timepoints
are indicated with letters a and b.
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Page 5 of 8In the infrarenal region (EVO/n-3 0.88 ± 0.58%, CORN
1.17 ± 0.48%, and control group 1.62 ± 0.33%), the reduc-
tion was not significant.
In the male mice, differences were only weak, and the
only significant reduction were observed in the thora-
coabdominal region of the aorta, were the plaque bur-
den were significantly less in the male apoE-deficient
mice fed diets enriched with the combination of EVO/
n-3, compared to the control mice. There were no visi-
ble atherosclerotic lesions in any area of the aortas from
the chow (standard low-fat maintenance mouse feed)
fed apoE-deficient male mice (data not shown).
Discussion
The purpose of this study was to investigate the effect of
dietary supplementation of apoE-deficient mice with
EVO in combination with seal oil on atherosclerotic
lesion formation. The rationale for combining the refined
marine oil with EVO high in antioxidative phenolic com-
pounds was to combine the beneficial effects of both
these dietary oils, and furthermore to prevent the poten-
tial harmful effects related to oxidation of the highly
unsaturated n-3 fatty acids which is likely to occur in
milieus having low levels of antioxidants. In addition, it
has previously been observed that some beneficial effects
from crude marine oils are lost after refinement [14].
Improved anti-inflammatory and anti-platelet effects of
dietary supplementation with a cod liver (CLO)/olive oil
blend compared to separate supplementation with these
oils have previously been reported [8].
In support of our hypothesis, female mice fed diets
containing EVO/n-3 had reduced atherosclerotic lesion
formation throughout the entire aorta, whereas male
mice on the same diet only had a significantly reduced
lesion formation only in the abdominal region of the
aorta. The weaker response in male mice may be
explained by the atheroprotective effect of estrogen [15],
which reduce the atherosclerotic pressure and may
cause a situation where the effect of the supplementa-
tion in combination with a potential gender associated
estrogen effect results in reduced atherogenesis. Evi-
dence for an estrogen-dependent mechanism in the reg-
ulation of atherogenesis was recently reported in
apoE
-/--mice mediated via the heat shock protein 27
[16]. Thus, modulation of the release of this anti-athero-
genic protein may be one possibility for the effect of the
test oil in female mice. Other gender differences have
been associated with lesion formation in apoE
-/--mice
[17] and in a recent study; gender-specific n-3 PUFA-
related antiplatelet effects were observed when healthy
subjects were given EPA or DHA [18]. However, even
when results from both genders were combined, dietary
supplementation with EVO/n-3 significantly reduced
aortic lesion formation.
Lipid peroxidation plays an important role in athero-
genesis and the anti-atherogenic effect observed in the
EVO/n-3 group may at least partly be attributed to the
antioxidant compounds inherent in the cold pressed
olive oil [5,19,20]. EVO clearly protects the n-3 PUFA
against oxidation as the oxidograph experiments demon-
strate that the blend of EVO/n-3 is oxidized at 70°C
after 38 hrs compared to 0.2 hrs for the n-3 PUFA con-
centrate and 2.1 hrs for seal oil alone.
Thus, the EVO part of the EVO/n-3 combination
comprises potent antioxidants, particularly polyphenols
that may prevent the oxidation of the PUFAs and
thereby abolish modificationo fL D L - c h o l e s t e r o li nt h e
intima and subsequent oxidative stress [20]. Indeed, the
amount of polyphenols in olive oil has been demon-
strated to be correlated to both increases in HDL-
cholesterol and decreases in oxidative stress markers in
healthy humans [21]. The EVO antioxidants, which
probably play a central role in the investigated oil com-
bination, have recently been documented to contribute
to the health benefits derived from the Mediterranean
diet [5]. In addition, EVO and polyphenol-enriched
EVO have been demonstrated to moderately reduce
atherosclerosis in ApoE-deficient mice [22]. In combina-
tion with seal oil we suggest that these beneficial effects
may be accelerated. Interestingly, the combined oil pro-
duct of EVO/n-3 induces a strong stinging sensation in
the throat, associated with the presence of the anti-
inflammatory compound oleocanthal from the EVO
[23]. The present study indicated that marine oils might
contain other beneficial components of relevance for
CVD in addition to n-3 PUFA. Similarly, the combina-
tion of seal oil and cold pressed olive oil as used in this
study, was found to have superior beneficial effects
(anti-inflammatory and rise in HDL-cholesterol) com-
pared to CLO that contained much higher levels of n-3
PUFA in a clinical study of healthy individuals [9]. Our
studies suggest that by recombining refined seal oil, void
of antioxidants (removed through refinement) and other
contaminants, with extra virgin olive oil, a synergistic
effect is obtained between the marine PUFAs, particu-
larly EPA and DHA, and the powerful minor antioxidant
compounds in the olive oil, in addition to the high con-
centration of the monounsaturated oleic acid (n-9)
inherent in the EVO.
As generally recognized, dietary supplementation with
n-3 PUFA, here in combination with extra virgin olive
oil, reduced plasma triacylglycerol levels. In addition,
EVO/n-3 supplementation seemed to reduce plasma
total cholesterol. However, this effect was more pro-
nounced in the male mice, therefore the prevention of
atherogenesis observed in the EVO/n-3-enriched group
probably reflects the beneficial anti-inflammatory effect
previously observed in healthy humans where intake of
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Page 6 of 815 ml/day in 10 weeks of EVO/seal oil caused a mean
reduction of 14.3% in monocyte chemotactic protein-1
(MCP-1) and 24.0% hypersensitive CRP (hsCRP) com-
pared to respectively 5.2% and an increase of 12.5% for
intake of 15 ml fish oil (Østerud, personal communica-
tion). The corn oil diet contains significantly more
18:2n-6, compared to the other two diets, and improved
n-3/n-6 ratio caused by intake of n-3 PUFA from
the seal oil and less n-6 PUFA, are also considered
beneficial [12].
Direct anti-atherosclerotic activities of n-3 PUFA
remains to be demonstrated, however, several lines of
evidence suggest an beneficial effect of increased intake
of n-3 PUFA. Dietary n-3 PUFA (EPA, DPA, and DHA)
are incorporated into cell membranes and an important
effect of increased intake of n-3 PUFA is reduced release
of arachidonic acid and subsequent production of its
proinflammatory metabolites prostaglandins, leuko-
trienes and thromboxanes [24]. Recently, administration
of DHA was demonstrated to inhibit the activity of
secretory phospholipase A2 as well as to reduce the pro-
duction of superoxide via inhibition of NADPH oxidase
in endothelial cell cultures [25]. In addition, n-3 PUFA
compete with n-6 PUFA for access to receptors and
enzymes such as lipoxygenases and cyclooxygenases,
further reducing the potential in the circulation for acti-
vation of circulating platelets and other immunomodu-
lating cells. Both TxA2 and the 5-lipoxygenase pathway/
LTB4 have been indicated to be significant contributors
to atherogenesis in apoE-deficient mice [26-29]. In this
regard, the relatively high concentration of DPA in seal
oil compared to fish oil may at least partially account
for the atheroprotective effect of EVO/seal oil as it has
been shown that DPA is more potent than EPA and
DHA in inhibiting TxA2 formation. Furthermore, DPA
has been shown to reduce platelet activation in response
to collagen or arachidonic acid via enhanced formation
of 12-HETE [30]. It has previously been demonstrated
that the biological effects of marine oils do not directly
correlate to the total content of n-3 PUFA. Accordingly,
intake of cold pressed whale oil for 10 weeks in human
healthy volunteers resulted in beneficial effects such as
rise in HDL-cholesterol, reduced generation of pro-
inflammatory products in LPS-stimulated blood that was
superior to regular CLO despite the 50% lower content
of n-3 PUFA, but higher DPA content, in the whale oil
as compared to CLO [14]. Finally, it is evident that diet-
ary EPA is incorporated into advanced atherosclerotic
lesions resulting in decreased intravascular inflammation
and increased plaque stability [31,32].
Conclusions
This study demonstrates that EVO/n-3 supplementation
reduces atherosclerotic lesion formation, particularly in
female apoE-deficient mice. The antiatherogenic effect
o ft h eE V O / n - 3w a st os o m ee x t e n ta c c o u n t e df o rb y
lowering plasma total cholesterol and triacylglycerol
levels. The EVO rich in oleic acid and phenolic antioxi-
dants appears to work well in combination with a mar-
ine n-3 PUFA source providing atheroprotective
properties. This study needs to be followed up by
experiments exploring the biochemical and cellular
mechanisms responsible for the observed antiathero-
genic effect.
Acknowledgements
We are grateful to the animal facility at KULeuven, Belgium, for the routine
caretaking of the mice. This project was funded with grants from The
Research Council of Norway, the MABIT programme and Innovation Norway.
Professors Bjarne Østerud and Edel O. Elvevoll are acknowledged for
providing the Olivita (EVO/n-3) oil blend in addition to invaluable
discussions throughout the study. The study was conducted at KULeuven,
Belgium, where K.E. Eilertsen was a visiting research fellow.
Author details
1Norwegian College of Fishery Science, University of Tromsø, Tromsø,
Norway.
2MabCent-SFI, University of Tromsø, Tromsø, Norway.
3Center for
Molecular and Vascular Biology, Katholieke Universiteit Leuven, Leuven,
Belgium.
4HERG, Department of Medical Biology, Faculty of Health Sciences,
Tromsø, Norway.
Authors’ contributions
All authors contributed to the intellectual development of this study, and
approved the final manuscript. KEE conceived the study, participated in
experimental design, prepared the diets, carried out the animal experiments,
did the sampling and prepared the samples, performed the lesion analyses
and statistical analysis, and drafted the manuscript. HKM carried out the fatty
acid analyses and provided critical corrections to the manuscript. KC
handled the animals, prepared and handled the diets and prepared samples,
MFH conceived the study, participated in experimental design, contributed
with experimental expertise and provided critical corrections to the
manuscript. JOO carried out lesion analyses.
Declaration of competing interests
The authors declare that they have no competing interests.
Received: 27 January 2011 Accepted: 3 March 2011
Published: 3 March 2011
References
1. Covas MI, Konstantinidou V, Fitó M: Olive oil and cardiovascular health. J
Cardiovasc Pharmacol 2009, 54:477-482.
2. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N:
Mediterranean diet, traditional risk factors, and the rate of
cardiovascular complications after myocardial infarction: Final report of
the Lyon Diet Heart Study. Circulation 1999, 99:779-785.
3. Buckland G, González CA, Agudo A, Vilardell M, Berenguer A, Amiano P,
Ardanaz E, Arriola L, Barricarte A, Basterretxea M, Chirlaque MD, Cirera L,
Dorronsoro M, Egües N, Huerta JM, Larrañaga N, Marin P, Martínez C,
Molina E, Navarro C, Quirós JR, Rodriguez L, Sanchez MJ, Tormo MJ,
Moreno-Iribas C: Adherence to the Mediterranean Diet and Risk of
Coronary Heart Disease in the Spanish EPIC Cohort Study. Am J
Epidemiol 2009, 170:1518-1529.
4. Trichopoulou A, Costacou T, Bamia C, Trichopoulos D: Adherence to a
Mediterranean diet and survival in a Greek population. N Engl J Med
2003, 348:2599-2608.
5. Covas MI, Ruiz-Gutiérrez V, de la Torre R, Kafatos A, Lamuela-Raventós RM,
Osada J, Owen RW, Visioli F: Minor Components of Olive Oil: Evidence to
Date of Health Benefits in Humans. Nutr Rev 2006, 64:S1-S11.
6. López-Miranda J, Pérez-Jiménez F, Ros E, De Caterina R, Badimón L,
Covas MI, Escrich E, Ordovás JM, Soriguer F, Abiá R, de la Lastra CA,
Eilertsen et al. Lipids in Health and Disease 2011, 10:41
http://www.lipidworld.com/content/10/1/41
Page 7 of 8Battino M, Corella D, Chamorro-Quirós J, Delgado-Lista J, Giugliano D,
Esposito K, Estruch R, Fernandez-Real JM, Gaforio JJ, La Vecchia C, Lairon D,
López-Segura F, Mata P, Menéndez JA, Muriana FJ, Osada J,
Panagiotakos DB, Paniagua JA, Pérez-Martinez P, Perona J, Peinado MA,
Pineda-Priego M, Poulsen HE, Quiles JL, Ramírez-Tortosa MC, Ruano J, Serra-
Majem L, Solá R, Solanas M, Solfrizzi V, de la Torre-Fornell R,
Trichopoulou A, Uceda M, Villalba-Montoro JM, Villar-Ortiz JR, Visioli F,
Yiannakouris N: Olive oil and health: summary of the II international
conference on olive oil and health consensus report, Jaén and Córdoba
(Spain) 2008. Nutr Metab Cardiovasc Dis 2010, 20:284-94.
7. Bjerregaard P, Mulvad G, Pedersen HS: Cardiovascular risk factors in Inuit
of Greenland. Int J Epidemiol 1997, 26:1182-1190.
8. Vognild E, Elvevoll EO, Brox J, Olsen RL, Barstad H, Aursand M, Østerud B:
Effects of dietary marine oils and olive oil on fatty acid composition,
platelet membrane fluidity, platelet responses, and serum lipids in
healthy humans. Lipids 1998, 33:427-436.
9. Østerud B, Elvevoll EO: The combination of virgin olive oils and refined
marine oils. Beneficial effects. Progr Nutr 2008, 10:230-236.
10. Plump AS, Smith JD, Hayek T, Aaltosetala K, Walsh A, Verstuyft JG,
Rubin EM, Breslow JL: Severe Hypercholesterolemia and Atherosclerosis
in Apolipoprotein-E-Deficient Mice Created by Homologous
Recombination in Es Cells. Cell 1992, 71:343-353.
11. Zhang SH, Reddick RL, Piedrahita JA, Maeda N: Spontaneous
Hypercholesterolemia and Arterial Lesions in Mice Lacking
Apolipoprotein-E. Science 1992, 258:468-471.
12. Elvevoll EO, Barstad H, Breimo ES, Brox J, Eilertsen KE, Lund T, Olsen JO,
Østerud B: Enhanced incorporation of n-3 fatty acids from fish compared
with fish oils. Lipids 2006, 41:1109-1114.
13. Larsen KE: Methods for measuring autoxidation resistance. Proceedings of
the 15th Scandinavian symposium on lipids Lipidforum. Rebild Bakker
Denmark; 1989.
14. Østerud B, Elvevoll E, Barstad H, Brox J, Halvorsen H, Lia K, Olsen JO,
Olsen RL, Sissener C, Rekdal Ø, Vognild E: Effect of Marine Oils
Supplementation on Coagulation and Cellular Activation in Whole-
Blood. Lipids 1995, 30:1111-1118.
15. Cignarella A, Kratz M, Bolego C: Emerging role of estrogen in the control
of cardiometabolic disease. Trends Pharmacol Sci 2010, 31:183-189.
16. Rayner K, Sun J, Chen YX, McNulty M, Simard T, Zhao X, Wells Belleroche J,
O’Brien ER: Heat Shock Protein 27 Protects Against Parthenogenesis via
an Estrogen-Dependent Mechanism: Role of Selective Estrogen Receptor
Beta Modulation. Arterioscler Thromb Vasc Biol 2009, 29:1751-1756.
17. Smith DD, Tan X, Milne G, Stechschulte DJ, Dileepan KN: Increased aortic
atherosclerotic plaque development in female apolipoprotein E-null
mice is associated with elevated thromboxane A2 and decreased
prostacyclin production. J Physiol Pharmacol 2010, 61:309-316.
18. Phang M, Sinclair AJ, Lincz LF, Garg ML: Gender-specific inhibition of
platelet aggregation following omega-3 fatty acid supplementation. Nutr
Metab Cardiovasc Dis 2010.
19. Bogani P, Galli C, Villa M, Visioli F: Postprandial anti-inflammatory and
antioxidant effects of extra virgin olive oil. Atherosclerosis 2007,
190:181-186.
20. Visioli F, Bellomo G, Montedoro G, Galli C: Low density lipoprotein
oxidation is inhibited in vitro by olive oil constituents. Atherosclerosis
1995, 117:25-32.
21. Covas MI, Nyyssönen K, Poulsen HE, Kaikkonen J, Zunft HJ, Kiesewetter H,
Gaddi A, de la Torre R, Mursu J, Bäumler H, Nascetti S, Salonen JT, Fitó M,
Virtanen J, Marrugat J, EUROLIVE Study Group: The effect of polyphenols
in olive oil on heart disease risk factors: a randomized trial. Ann Intern
Med 2006, 145:333-341.
22. Rosenblat M, Volkova N, Coleman R, Almagor Y, Aviram M:
Antiatherogenicity of extra virgin olive oil and its enrichment with green
tea polyphenols in the atherosclerotic apolipoprotein-E-deficient mice:
enhanced macrophage cholesterol efflux. J Nutr Biochem 2008,
19:514-523.
23. Calder PC: The relationship between the fatty acid composition of
immune cells and their function. Prostaglandins Leukot Essent Fatty Acids
2008, 79:101-108.
24. Zhuge X, Arai H, Xu Y, Murayama T, Kobayashi T, Narumiya S, Kita T,
Yokode M: Protection of atherogenesis in thromboxane A2 receptor-
deficient mice is not associated with thromboxane A2 receptor in bone
marrow-derived cells. Biochem Biophys Res Commun 2006, 351:865-871.
25. Richard D, Wolf C, Barbe U, Kefi K, Bausero P, Visioli F: Docosahexaenoic
acid down-regulates endothelial Nox 4 through a sPLA2 signalling
pathway. Biochem Biophys Res Commun 2009, 389:516-522.
26. Heller EA, Liu E, Tager AM, Sinha S, Roberts JD, Koehn SL, Libby P,
Aikawa ER, Chen JQ, Huang P, Freeman MW, Moore KJ, Luster AD,
Gerszten RE: Inhibition of atherogenesis in BLT1-deficient mice reveals a
role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation
2005, 112:578-586.
27. Kaur G, Cameron-Smith D, Garg M, Sinclair AJ: Docosapentaenoic acid
(22:5n-3): A review of its biological effects. Prog Lipid Res 2010, 50:28-34.
28. Beauchamp GK, Keast RS, Morel D, Lin J, Pika J, Han Q, Lee CH, Smith AB,
Breslin PA: Phytochemistry: ibuprofen-like activity in extra-virgin olive oil.
Nature 2005, 437:45-46.
29. Mehrabian M, Allayee H, Wong J, Shih WB, Wang XP, Shaposhnik Z,
Funk CD, Lusis AJ: Identification of 5-lipoxygenase as a major gene
contributing to atherosclerosis susceptibility in mice. Circ Res 2002,
91:120-126.
30. Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA: The
thromboxane receptor antagonist S18886 but not aspirin inhibits
atherogenesis in apo E-deficient mice - Evidence that eicosanoids other
than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc
Biol 2000, 20:1724-28.
31. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP,
Gallagher PJ, Calder PC, Grimble RF: Association of n-3 polyunsaturated
fatty acids with stability of atherosclerotic plaques: a randomised
controlled trial. Lancet 2003, 361:477-485.
32. Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJ,
Gudmundsen O, Vige R, Payne SP, Ye S, Shearman CP, Gallagher PJ,
Grimble RF, Calder PC: Eicosapentaenoic acid (EPA) from highly
concentrated n-3 fatty acid ethyl esters is incorporated into advanced
atherosclerotic plaques and higher plaque EPA is associated with
decreased plaque inflammation and increased stability. Atherosclerosis
2010, 212:252-259.
doi:10.1186/1476-511X-10-41
Cite this article as: Eilertsen et al.: Dietary enrichment of apolipoprotein
E-deficient mice with extra virgin olive oil in combination with seal oil
inhibits atherogenesis. Lipids in Health and Disease 2011 10:41.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Eilertsen et al. Lipids in Health and Disease 2011, 10:41
http://www.lipidworld.com/content/10/1/41
Page 8 of 8